UCB

UCB

UCB S.A. functions as the family office for the Janssen family, whose wealth originates from the eponymous pharmaceutical company founded by Emmanuel Janssen in Brussels in 1928. The group rose to global prominence through blockbuster drugs treating central nervous system disorders and allergies, particularly Zyrtec and Keppra. Rather than consolidating holdings under a corporate parent, the family separates the operating company — UCB Pharma, now a publicly traded entity — from its investment arm, which manages shareholding proceeds and diversified family capital. The family office pursues a mixed-asset strategy spanning venture capital, private equity, real estate, and biotech. In venture, UCB S.A. participates in early and growth-stage biotechnology firms, complementing the drug-development ecosystem the family knows intimately. Notable positions include historical portfolio exposure to immunotherapy and CNS-focused startups in Belgium and the United States. The real estate arm holds commercial and residential assets in prime locations, including properties in Brussels, Montreal, and the Northeast United States, often held directly rather than through funds. The office also commits to third-party private equity funds to access mid-market buyout opportunities in North America and Europe, occasionally co-investing alongside trusted managers. Operating from Brussels with satellite presences in Menlo Park, New York, Montreal, Baltimore, and Boston, UCB S.A. maintains a lean team that blends family members with external investment professionals hired for direct and fund-investment expertise. The North American offices extend the firm's capacity to source healthcare-adjacent deals and maintain proximity to biotech hubs. While the office does not publicly disclose total assets, the Janssen family's stake in UCB Pharma alone has historically been valued in the billions, placing UCB S.A. among Europe's significant single-family offices. The office's distinct architecture lies in its dual identity: it is neither a pure family office nor a corporate venture arm, but a permanent capital vehicle whose life-science DNA gives it a genuine sourcing advantage in healthtech. Unlike many peers that outsource thematic exposure, UCB S.A. can diligence preclinical-stage assets with pharmaceutical depth, a structural edge few non-operating family offices possess.